Two Vitamins Share a Name, but Only One Is Protecting Your Arteries and Bones

A Single Letter, Two Entirely Different Biological Roles

Vitamin K occupies a peculiar position in mainstream nutrition. It appears on food labels, it shows up in leafy green vegetables, and most adults assume they are getting enough of it. Yet the term "vitamin K" is something of a misnomer when applied as a single concept—because the two principal forms of this nutrient, K1 (phylloquinone) and K2 (menaquinone), behave quite differently once inside the body, and they do not serve the same tissues in the same way.

Phylloquinone, or K1, is abundant in spinach, kale, broccoli, and other dark leafy greens. Its primary and well-established function is hepatic: it supports the liver's synthesis of clotting factors, which is why patients on blood-thinning medications like warfarin are counseled to monitor their intake of these foods. This is the vitamin K that standard dietary guidelines track, and it is the form most Americans encounter when they think about the nutrient at all.

Menaquinone, or K2, is a different matter entirely. Found in fermented foods, certain aged cheeses, and organ meats—none of which feature prominently in the average American diet—K2 is the form that activates proteins responsible for directing calcium to the right locations in the body. That distinction, while it may sound technical, has profound implications for arterial health, bone density, and metabolic function.

The Calcium Routing Problem

Calcium is essential. It builds and maintains bone structure, supports muscle contraction, and plays a role in nerve signaling. But calcium deposited in the wrong place—specifically, inside arterial walls—is associated with cardiovascular disease, reduced arterial elasticity, and increased risk of cardiac events. This phenomenon, known as vascular calcification, is not simply a consequence of eating too much calcium. It is, in significant part, a consequence of inadequate activation of the proteins that keep calcium out of soft tissues.

Two proteins are central to this process: osteocalcin, which binds calcium into bone matrix, and matrix Gla protein (MGP), which actively inhibits calcium from accumulating in blood vessel walls. Both proteins require vitamin K2 to become biologically active through a process called carboxylation. Without sufficient K2, these proteins remain in their inactive, undercarboxylated state—unable to perform their regulatory functions regardless of how much calcium or vitamin D a person consumes.

This is where the clinical picture becomes compelling. Research published in journals including the Journal of Nutrition and Thrombosis and Haemostasis has found associations between higher dietary K2 intake and reduced coronary calcification and cardiovascular mortality. The Rotterdam Study, a large prospective cohort conducted in the Netherlands, found that participants with the highest K2 intake had significantly lower rates of aortic calcification and coronary heart disease compared to those with the lowest intake—an association that was not observed with K1 intake. The implication is that the two forms are not interchangeable, and that the form most Americans are consuming is not the one with the strongest evidence for vascular protection.

What the Bone Density Data Reveals

Osteoporosis affects an estimated 10 million Americans, with another 44 million classified as having low bone density. Standard preventive strategies focus on calcium and vitamin D, and while both are genuinely important, the emerging research on K2 suggests that this framework is incomplete.

Osteocalcin, the bone-binding protein mentioned above, requires K2-dependent carboxylation to incorporate calcium effectively into bone tissue. Studies examining populations with higher K2 intake—particularly in Japan, where natto, a fermented soybean product and one of the richest dietary sources of K2, is consumed regularly—have found lower rates of hip fracture and better bone mineral density outcomes compared to Western populations with comparable calcium intake. Clinical trials using supplemental menaquinone-7 (MK-7), a long-chain form of K2 with high bioavailability, have demonstrated improvements in bone strength markers and reduced rates of vertebral fracture in postmenopausal women.

The mechanism is straightforward: more activated osteocalcin means more efficient calcium binding in bone. The clinical outcome is a skeleton that retains its density more effectively over time. Yet K2 remains absent from most standard osteoporosis prevention protocols in the United States.

Why American Diets Fall Short on K2

The foods richest in K2 are not the foods Americans eat in abundance. Natto, the Japanese fermented soybean dish that delivers the highest concentrations of MK-7, is rarely found outside specialty Asian grocery stores. Hard and aged cheeses such as Gouda and Brie contain meaningful amounts of K2, as do egg yolks and certain organ meats—foods that have been either marginalized by low-fat dietary trends or simply absent from most people's regular eating patterns.

By contrast, K1 is easy to consume. A single serving of cooked kale or spinach provides several times the current daily adequate intake for vitamin K as a whole. But because dietary guidelines do not distinguish between K1 and K2 in their recommendations, meeting the general vitamin K threshold through leafy greens creates a false sense of sufficiency. A person eating a nutritionally conscientious American diet may be well-supplied with K1 and almost entirely depleted of K2—a distinction the standard bloodwork panel does not typically detect.

The Supplementation Question

For individuals seeking to address a likely K2 gap, supplementation has become the most practical option given the dietary landscape. K2 supplements are available primarily in two forms: MK-4 and MK-7. MK-4 has a shorter half-life in circulation and typically requires multiple daily doses to maintain blood levels; MK-7, derived from natto fermentation, has a significantly longer half-life and is generally considered the more bioavailable and convenient option in supplement form.

One important clinical consideration: individuals taking anticoagulant medications, particularly warfarin, should consult their physician before adding any form of vitamin K supplementation. While K2 does not appear to affect clotting factor synthesis to the same degree as K1, the interaction between vitamin K and anticoagulant therapy requires medical oversight. For otherwise healthy adults, K2 supplementation in the ranges studied clinically—typically 90 to 360 micrograms per day of MK-7—has demonstrated a favorable safety profile.

At Dr. Zoh Wellness, we believe that precision matters in supplementation. The distinction between K1 and K2 is not a marketing nuance—it reflects a genuine divergence in biological function that has material consequences for long-term health outcomes.

Rethinking the Conventional Framework

The story of vitamin K2 is, in many ways, a story about the limits of nutritional reductionism. When a nutrient is classified under a single umbrella and assessed against a single reference value, the complexity of its real-world function gets compressed into a figure that may not tell the full story. Adequate vitamin K intake, as currently defined, does not guarantee adequate K2 status—and K2 status, as the evidence increasingly suggests, is what matters most for arterial health and bone integrity.

This is not a fringe position. It is a conclusion supported by epidemiological data, controlled trials, and a mechanistic understanding of how calcium is regulated in human physiology. The question for health-conscious Americans is not whether to consume more leafy greens—that remains sound advice—but whether the K2 gap in their diets deserves the same attention that vitamin D deficiency has received over the past two decades.

The evidence suggests it does.